EGFR and neoplasm: Tumor mutant peptides presented on the cell surface by HLA I molecules (e.g., KRAS G12V, EGFR L858R) as tumor-specific antigens (TSAs, also called neoantigens), are likely favorable targets for TCRm-ADCs since they are solely present on tumor cell surfaces, although it is still difficult so far for us to screen the specific TCRm antibodies which can discriminate between the wild types and mutant forms of the antigenic peptides, especially when some mutant residues are shielded by the HLA-I molecules [40].